HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy

被引：0
|
作者：
Zhao, Jing [1 ]
Meisel, Jane [2 ]
Suo, Aili [3 ]
Zhang, Chao [4 ]
Wei, Zhimin [1 ]
Aneja, Ritu [5 ]
Li, Zaibo [6 ]
Nahta, Rita [2 ]
Li, Xiaoxian [2 ]
机构：
[1] Qingdao Univ, Affiliated Hosp, Qingdao, Shandong, Peoples R China
[2] Emory Univ, Atlanta, GA 30322 USA
[3] Xi An Jiao Tong Univ, Xian, Shaanxi, Peoples R China
[4] Winship Canc Inst, Atlanta, GA USA
[5] Georgia State Univ, Atlanta, GA 30303 USA
[6] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
来源：
MODERN PATHOLOGY | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
291
引用
收藏
页数：2
相关论文
共 50 条
  • [21] ERVMER34 sensitizes the response of HER2 positive breast cancer to neoadjuvant therapy
    Chi, Y.
    Ji, W.
    Xiu, B.
    Zhang, Q.
    Wu, J.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [22] Adjuvant therapy in breast cancer HER2 positive
    Olivito, V.
    De Simone, R.
    La Gattuta, G.
    Lucia, M.
    Dima, G.
    Talarico, R.
    Filippelli, G.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : VII146 - VII146
  • [23] Targeted therapy for HER2 positive breast cancer
    Jason A Incorvati
    Shilpan Shah
    Ying Mu
    Janice Lu
    [J]. Journal of Hematology & Oncology, 6
  • [24] Targeted therapy for HER2 positive breast cancer
    Incorvati, Jason A.
    Shah, Shilpan
    Mu, Ying
    Lu, Janice
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [25] Loss of HER2 expression in HER2-positive breast cancer patients after neoadjuvant therapy
    Sang, Yuting
    Wu, Jiong
    Yang, Benlong
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [26] Differential response of HER2 positive breast cancer based on HER2 protein expression level
    Atallah, N. M.
    Toss, M. S.
    Al Saleem, M.
    Green, A. R.
    Mongan, N. P.
    Rakha, E. A.
    [J]. JOURNAL OF PATHOLOGY, 2023, 261 : S9 - S9
  • [27] Correlation between HER2 amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2 positive breast cancer.
    Antolin, Silvia
    Garcia-Caballero, Lucia
    Reboredo, Cristina
    Molina Diaz, Aurea
    Mosquera, Joaquin
    Vazquez-Boquete, Angel
    Gallego, Rosalia
    Paz Santiago, Maria
    Concha, Angel
    Eva Perez, Maria
    Calvo, Lourdes
    Garcia-Caballero, Tomas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
    Zheng-Jun Yang
    Fei Xin
    Zu-Jin Chen
    Yue Yu
    Xin Wang
    Xu-Chen Cao
    [J]. BMC Cancer, 24
  • [29] Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
    Yang, Zheng-Jun
    Xin, Fei
    Chen, Zu-Jin
    Yu, Yue
    Wang, Xin
    Cao, Xu-Chen
    [J]. BMC CANCER, 2024, 24 (01)
  • [30] Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
    Guarneri, V.
    Barbieri, E.
    Dieci, M. V.
    Piacentini, F.
    Conte, P.
    [J]. CANCER TREATMENT REVIEWS, 2010, 36 : S62 - S66
12345